From WikiPathways
(Difference between revisions)
|
|
Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
- |
| |
- | {{{{FULLPAGENAME}}/box-title
| |
- | |<!-- TITLE OF BOX -->
| |
- | <big>Welcome to the COVID-19 Pathways Portal on WikiPathways</big>
| |
- | |<!-- EDIT LINK -->
| |
- | {{FULLPAGENAME}}/Intro
| |
- | |<!-- CONTENT LINK -->
| |
- | {{FULLPAGENAME}}/Intro
| |
- | |<!-- FOOTER LINK -->
| |
- | }}
| |
- |
| |
- | <div style="float:left; width:62%"> <!-- This width add to the the margin below to equal 99%-->
| |
- |
| |
- | {{{{FULLPAGENAME}}/box-normal
| |
- | |<!-- TITLE OF BOX -->
| |
- | Covered Pathways
| |
- | |<!-- EDIT LINK -->
| |
- | {{FULLPAGENAME}}/CoveredPWs
| |
- | |<!-- CONTENT LINK -->
| |
- | {{FULLPAGENAME}}/CoveredPWs
| |
- | |<!-- FOOTER LINK -->
| |
- | }}
| |
- |
| |
- | {{{{FULLPAGENAME}}/box-normal
| |
- | |<!-- TITLE OF BOX -->
| |
- | Contribute
| |
- | |<!-- EDIT LINK -->
| |
- | {{FULLPAGENAME}}/Contribute
| |
- | |<!-- CONTENT LINK -->
| |
- | {{FULLPAGENAME}}/Contribute
| |
- | |<!-- FOOTER LINK -->
| |
- | }}
| |
- |
| |
- | </div>
| |
- |
| |
- | <div style="float:right; width:37%"> <!-- This margin should be right of the above -->
| |
- |
| |
- | {{{{FULLPAGENAME}}/box-normal
| |
- | |<!-- TITLE OF BOX -->
| |
- | Featured Pathway
| |
- | |<!-- EDIT LINK -->
| |
- | {{FULLPAGENAME}}/FeaturedPathways
| |
- | |<!-- CONTENT LINK -->
| |
- | {{FULLPAGENAME}}/Featured
| |
- | |<!-- FOOTER LINK -->
| |
- | }}
| |
- |
| |
- | {{{{FULLPAGENAME}}/box-normal
| |
- | |<!-- TITLE OF BOX -->
| |
- | News
| |
- | |<!-- EDIT LINK -->
| |
- | {{FULLPAGENAME}}/News
| |
- | |<!-- CONTENT LINK -->
| |
- | {{FULLPAGENAME}}/News
| |
- | |<!-- FOOTER LINK -->
| |
- | }}
| |
- |
| |
- |
| |
- | </div>
| |
- |
| |
- | <!--
| |
- | {{{{FULLPAGENAME}}/box-title
| |
- | |<!-- TITLE OF BOX --> <!--
| |
- | <big>Participating Projects and Institutes</big>
| |
- | |<!-- EDIT LINK --><!--
| |
- | {{FULLPAGENAME}}/Participants
| |
- | |<!-- CONTENT LINK --><!--
| |
- | {{FULLPAGENAME}}/Participants
| |
- | |<!-- FOOTER LINK --> <!--
| |
- | }}
| |
- | -->
| |
- |
| |
| | | |
| {|style="margin: 10px;" | | {|style="margin: 10px;" |
Revision as of 11:16, 9 September 2020
Welcome to the COVID-19 Pathway Collection
This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection.
The current list of authors and contributors of content of this portal: Friederike Ehrhart, Alex Pico, Kristina Hanspers, Amber Koning, Rex D A B, Penny Nymark, Denise Slenter, Caroline Thorn, the Reactome project, Chris Evelo, Lauren Dupuis, Matthew Conroy, Martina Kutmon, Marvin Martens, and many more.
We also thank the authors of all the cited articles (recursively).
|
|
SARS-CoV-2 Pathways
Image does not exist SARS-CoV-2 and COVID-19 Pathway
Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection.
|
Image does not exist Hijack of Ubiquitination by SARS-CoV-2
SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex.
|
Image does not exist Type I Interferon Induction and Signaling During SARS-CoV-2 Infection
The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug.
|
Image does not exist COVID-19, thrombosis and anticoagulation
|
Image does not exist Activation of NLRP3 Inflammasome by SARS-CoV-2
Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome.
|
Image does not exist SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target
|
Image does not exist COVID-19 AOP
Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways
|
Image does not exist nsp9/nsp10-mediated SARS-CoV-2 pathogenesis
Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis
|
Image does not exist LDLRAD4 pathway in COVID-19
|
Image does not exist Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)
|
Other coronaviruses: MERS, SARS-CoV, etc
Image does not exist Coronavirus lipid metabolism
Lipid metabolism alternations that are related to infection by the corona virus.
|
Image does not exist Host-pathogen interaction of human corona viruses - autophagy
|
Image does not exist Host-pathogen interaction of human corona viruses - apoptosis
|
Image does not exist SARS coronavirus and innate immunity
|
Image does not exist ER stress response in Coronavirus infection
|
Image does not exist Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein
|
Image does not exist Host-pathogen interaction of human corona viruses - MAPK signaling
|
Image does not exist Host-pathogen interaction of human corona viruses - Interferon induction
|
More about ACE2
Image does not exist ACE Inhibitor Pathway
|
Image does not exist Metabolism of Angiotensinogen to Angiotensins (Reactome)
|